Apex Biotechnology (TPE:1733) Total Stockholders Equity: NT$1,859 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1733 Apex Biotechnology Corp TPE:1733
82 GF Score
Price NT$29.90
GF Value NT$29.96
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Apex Biotechnology Total Stockholders Equity?

Apex Biotechnology TPE:1733 -1.48% 82 Total Stockholders Equity is NT$1,859 Mil as of Jun. 2026. GuruFocus rates TPE:1733 with a GF Score™ of 82/100 and a GF Value™ of NT$29.96 (Fairly Valued). The stock has 3 warning signs investors should review.

Apex Biotechnology's Total Stockholders Equity for the quarter that ended in Jun. 2026 was NT$1,859 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Apex Biotechnology's Book Value per Share for the quarter that ended in Jun. 2026 was NT$18.60. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Apex Biotechnology's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.02.

Apex Biotechnology  (TPE:1733) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Apex Biotechnology's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1858.767-0)/99.95
=18.60

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Apex Biotechnology's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(43.426 + 0) / 1858.767
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology Total Stockholders Equity Related Terms

Apex Biotechnology Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Apex Biotechnology's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology Total Stockholders Equity Chart

Apex Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,752.73 1,817.32 1,796.43 1,823.60 1,869.72

Apex Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,790.47 1,814.10 1,869.72 1,821.92 1,858.77
TPE:1733
82GF Score
Apex Biotechnology Corp TPE:1733
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of NT$1,859 Mil mean?
Apex Biotechnology (TPE:1733) has a Total Stockholders Equity of NT$1,859 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Apex Biotechnology and its competitors.
Is Apex Biotechnology's Total Stockholders Equity too high?
Apex Biotechnology's current Total Stockholders Equity is NT$1,859 Mil. Overall, Apex Biotechnology has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Total Stockholders Equity compare to VRTX and REGN?
Apex Biotechnology's Total Stockholders Equity of NT$1,859 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Apex Biotechnology and its competitors. Apex Biotechnology's current Total Stockholders Equity is NT$1,859 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.96, compared to a current price of NT$29.90 — trading 0.2% below its estimated fair value. The current Total Stockholders Equity is NT$1,859 Mil. Apex Biotechnology's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Total Stockholders Equity is NT$1,859 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apex Biotechnology (TPE:1733) Overvalued in 2026?

Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued. The current stock price of NT$29.90 is trading 0.2% below its estimated GF Value™ of NT$29.96. GuruFocus considers Apex Biotechnology to be Fairly Valued.

Key valuation signals for TPE:1733:

  • Total Stockholders Equity: NT$1,859 Mil
  • GF Value™: NT$29.96 vs. price of NT$29.90 (0.2% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apex Biotechnology Business Description

Address Li-Hsin 5th Road, No. 7, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
82GF Score

Get the complete analysis for TPE:1733

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.90
Price
NT$29.96
GF Value